## AMENDMENT TO THE CLAIMS

The Listing of Claims presented below will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound having the structure:

$$R_1O$$
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 
 $R_5$ 
 $R_6$ 
 $R_7$ 
 $R_8$ 

wherein R<sub>1</sub>-R<sub>4</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety;

R<sub>5</sub> and R<sub>6</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein R<sub>6</sub> and R<sub>7</sub>, taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety;

wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted; and

pharmaceutically acceptable derivatives thereof.

2. (Original) The compound of claim 1, wherein the compound has the structure (II):

$$R_1O_{M_{M_1}}$$
 $R_2$ 
 $R_3$ 
 $R_3$ 
(II)

Page 2 of 12

wherein R<sub>1</sub>-R<sub>4</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety;

R<sub>5</sub> and R<sub>6</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein R<sub>6</sub> and R<sub>7</sub>, taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety;

wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted; and

pharmaceutically acceptable derivatives thereof.

- 3. (Original) The compound of claim 1, wherein  $R^1$  is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen,  $-(CH_2)_qOR^Z$ ,  $-(CH_2)_qSR^Z$ ,  $-(CH_2)_qN(R^Z)_2$ ,  $-(C=O)N(R^Z)_2$ , or an aliphatic, heteroaliphatic, aryl, heteroaryl, (aliphatic)aryl, (aliphatic)heteroaryl, (heteroaliphatic)aryl, or (heteroaliphatic)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of  $R^Z$  is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, (aliphatic)aryl, (aliphatic)heteroaryl, (heteroaliphatic)aryl, or (heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, (alkyl)aryl, (alkyl)heteroaryl, (heteroalkyl)aryl, or (heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.
- (Original) The compound of claim 3, wherein R<sup>1</sup> is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or -(lower alkyl)phenyl moiety, -(CH<sub>2</sub>)<sub>n</sub>OR<sup>2</sup>, -[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>R<sup>2</sup>, -(CH<sub>2</sub>)<sub>n</sub>-Ar-(CH<sub>2</sub>)<sub>m</sub>OR<sup>2</sup>; wherein n and m are each independently integers from 1-6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R<sup>2</sup> is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or

Page 3 of 12

unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.

5. (Original) The compound of claim 4, wherein R<sup>1</sup> is hydrogen, ethyl, or has one of the structures:

$$R^{2}O$$
 $R^{2}O$ 
 $R^{2}O$ 

wherein Rz is as defined in claim 4.

- 6. (Original) The compound of claim 1, wherein  $R^2$  is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen,  $-(CH_2)_qOR^Z$ ,  $-(CH_2)_qSR^Z$ ,  $-(CH_2)_qN(R^Z)_2$ ,  $-(C=O)R^Z$ ,  $-(C=O)N(R^Z)_2$ , or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(beteroaliphatic)aryl, or -(beteroaliphatic)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of  $R^Z$  is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(beteroaliphatic)aryl, or -(beteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(beteroalkyl)aryl, or -(beteroalkyl)aryl, or -(beteroalkyl)aryl, or -(beteroalkyl)aryl, or -(beteroalkyl)heteroaryl moieties may be substituted or unsubstituted.
- 7. (Original) The compound of claim 6, wherein R<sup>2</sup> is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or —(lower alkyl)phenyl moiety, -(CH<sub>2</sub>)<sub>n</sub>OR<sup>z</sup>, -[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>R<sup>z</sup>, -(CH<sub>2</sub>)<sub>n</sub>-A<sub>I</sub>-(CH<sub>2</sub>)<sub>m</sub>OR<sup>z</sup>; wherein n and m are each independently integers from 1-6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R<sup>z</sup> is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -

Page 4 of 12

(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or --(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.

(Original) The compound of claim 6, wherein R<sup>2</sup> is hydrogen or has one of the 8. structures:

wherein Rz is as defined in claim 6.

- (Original) The compound of claim 1, wherein R3 is an alkyl, heteroalkyl, aryl, 9. heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or --(heteroalkyl)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.
- (Original) The compound of claim 9, wherein R<sup>3</sup> has one of the structures: 10.

(Original) The compound of claim 1, wherein R4 is hydrogen or an alkyl, heteroalkyl, 11. aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.

- 12. (Original) The compound of claim 11, wherein R<sup>4</sup> is hydrogen alkyl or heteroalkyl.
- 13. (Original) The compound of claim 1, wherein R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety; or wherein R<sup>5</sup> and R<sup>6</sup>, taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic moiety comprising 5-12 carbon atoms, 0-5 oxygen atoms, 0-5 sulfur atoms and 1-5 nitrogen atoms; and wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.
- 14. (Original) The compound of claim 1, wherein -NR<sup>5</sup>R<sup>6</sup> is one of the following the structures:

15. (Original) The compound of claim 1 having the structure:

16. (Original) The compound of claim 1 having the structure:

Page 7 of 12

Attorney Docket No.: 2001180-0077 (HU 2060-02 US NATL)

17. (Currently Amended) [The] A compound [of claim 1] having the structure:

18. (Original) The compound of claim 1 having the structure:

19. (Original) The compound of claim 1 having the structure:

(Original) The compound of claim 1 having the structure: 20.

(Previously Amended) The compound of claim I having the structure: 21.

(Currently Amended) [The] A compound [of claim 1] having the structure: 22.

- (Original) A collection of compounds comprising two or more of the compounds of 23. claim 1 or 2.
- (Original) The collection of claim 23, wherein the collection is provided in array format. 24.

Page 9 of 12

Attorney Docket No.: 2001180-0077 (HU 2060-02 US NATL)

- 25. (Original) The collection of claim 23, wherein the collection is provided in array format on a glass slide.
- 26. (Original) The collection of claim 23, wherein the collection comprises at least 100 compounds.
- (Original) The collection of claim 23, wherein the collection comprises at least 1,000 27. compounds.
- (Original) The collection of claim 23, wherein the collection comprises at least 2,000 28. compounds.
- (Original) The collection of claim 23, wherein the collection comprises at least 10,000 29. compounds.
- 30. (Original) A pharmaceutical composition comprising: a compound of any one of claims 1, 2, 5, 8, 10, 14, and 15-22; and a pharmaceutically acceptable carrier.

Claims 31-39. Canceled